Bone Metabolism Analytes as Biomarkers of Pre-Frailty and Cardiovascular Disease Risk in Females-Advances in Geriatric Medicine and Research-CSCIED科技核心评价数据库-手机版

Bone Metabolism Analytes as Biomarkers of Pre-Frailty and Cardiovascular Disease Risk in Females

Bone Metabolism Analytes as Biomarkers of Pre-Frailty and Cardiovascular Disease Risk in Females

ES评分 0 浏览量：608 下载量：0

DOI	10.20900/agmr20200025
刊名	Advances in Geriatric Medicine and Research AGMR
年，卷(期)	2020, 2(4)
作者	Kevin F. Boreskie,Christopher J. Oldfield,Liam A.Thompson,Teri L. Moffatt,Brett M. Hiebert,Rakesh C. Arora,Todd A. Duhamel*,
作者单位	Faculty of Kinesiology and Recreation Management, University of Manitoba, Winnipeg, Manitoba R2H 2N2, Canada ; Cardiac Sciences Program, Winnipeg Regional Health Authority, Winnipeg, Manitoba R2H 2A6, Canada ; Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, Manitoba R2H 2A6, Canada ;
Abstract	Background: Frailty and cardiovascular disease (CVD) share common pathophysiology in their progression. Declines in bone health often occur concomitantly with frailty and CVD. Therefore, analytes of bone metabolism may be useful biomarkers of pre-frailty and CVD risk. The aim of this study was to identify the effects of pre-frailty and CVD risk on the systemic concentrations of bone metabolism and inflammatory analytes in middle-aged and older females.Method: This case-control study is a secondary analysis of data from 1030 females with no self-reported history of CVD. Frailty was measured using the Fried Criteria, and females were stratified into low and elevated CVD risk using the Framingham risk score. Greedy matching with pre-frailty as the exposure variable identified 26 matched pairs in the low and elevated CVD risk groups for a total of 104 females. Factorial ANOVA compared differences in the log transformed concentrations of 15 bone metabolism analytes based on pre-frailty status, CVD risk, and the interaction.Results: Differences in the systemic concentrations of IL-6 (5.25 ± 14.30 vs 1.35 ± 1.74 pg/mL, p = 0.001), TNFα (1.41 ± 1.83 vs 0.89 ± 0.40 pg/mL, p = 0.06), and leptin (12628.48 ± 10472.90 vs 7562.96 ± 4972.25 pg/mL, p = 0.023) were found in elevated CVD risk status compared to low. No differences in the concentrations of bone metabolism analytes were found based on pre-frailty status, nor were any interaction effects.Conclusion: Differences were found in the concentrations of cytokines involved in bone metabolism based on CVD risk; however, no differences were found based on pre-frailty status. IL-6, TNFα, and leptin may act as biomarkers of CVD risk, but this study does not support the use of the examined analytes involved in bone metabolism as biomarkers of pre-frailty.
KeyWord	frailty; cardiovascular disease; bone; bone metabolism analytes; biomarkers; females; aging
基金项目
页码	-

参考文献
相关文献

1.Statistics Canada. Canada’s population estimates: Age and sex, July 1, 2018. Available from: https://www150.statcan.gc.ca/n1/en/daily-quotidien/190125/dq190125a-eng.pdf?st=7PJeGKWj. Accessed 2020 Oct 15.

2.Seniors. Available from: https://www150.statcan.gc.ca/n1/pub/11-402-x/2011000/chap/seniors-aines/seniors-aines-eng.htm. Accessed 2020 Oct 15.

3.Kehler DS, Ferguson T, Stammers AN, Bohm C, Arora RC, Duhamel TA, et al. Prevalence of frailty in Canadians 18-79 years old in the Canadian Health Measures Survey. BMC Geriatr. 2017;17(1):28.

4.North BJ, Sinclair DA. The Intersection Between Aging and Cardiovascular Disease. Circ Res. 2012 Apr 13;110(8):1097-108.

5.Bergman H, Ferrucci L, Guralnik J, Hogan DB, Hummel S, Karunananthan S, et al. Frailty: An Emerging Research and Clinical Paradigm—Issues and Controversies. J Gerontol A Biol Sci Med Sci. 2007;62(7):731-7.

6.Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56.

7.Lang P-O, Michel J-P, Zekry D. Frailty syndrome: a transitional state in a dynamic process. Gerontology. 2009;55(5):539-49.

8.Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health. 2018;3(7):e323-32.

9.Afilalo J, Karunananthan S, Eisenberg MJ, Alexander KP, Bergman H. Role of frailty in patients with cardiovascular disease. Am J Cardiol. 2009;103(11):1616-21.

10.Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505-22.

11.Flint K. Which came first, the frailty or the heart disease?: exploring the vicious cycle. J Am Coll Cardiol. 2015;65(10):984-6.

12.Farooqi MAM, Gerstein H, Yusuf S, Leong DP. Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154 000 Individuals. J Am Heart Assoc. 2020;9(3):e014686.

13.Veronese N, Cereda E, Stubbs B, Solmi M, Luchini C, Manzato E, et al. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. Ageing Res Rev. 2017;35:63-73.

14.Sergi G, Veronese N, Fontana L, De Rui M, Bolzetta F, Zambon S, et al. Pre-frailty and risk of cardiovascular disease in elderly men and women: the Pro.V.A. study. J Am Coll Cardiol. 2015;65(10):976-83.

15.Boreskie KF, Rose AV, Hay JL, Kehler DS, Costa EC, Moffatt TL, et al. Frailty status and cardiovascular disease risk profile in middle-aged and older females. Exp Gerontol. 2020 Aug 16;140:111061.

16.Gale CR, Cooper C, Sayer AA. Framingham cardiovascular disease risk scores and incident frailty: the English longitudinal study of ageing. Age Dordr Neth. 2014;36(4):9692.

17.Mitnitski A, Collerton J, Martin-Ruiz C, Jagger C, von Zglinicki T, Rockwood K, et al. Age-related frailty and its association with biological markers of ageing. BMC Med. 2015;13:161.

18.Lau ES, Paniagua SM, Guseh JS, Bhambhani V, Zanni MV, Courchesne P, et al. Sex Differences in Circulating Biomarkers of Cardiovascular Disease. J Am Coll Cardiol. 2019;74(12):1543-53.

19.Collerton J, Martin-Ruiz C, Davies K, Hilkens CM, Isaacs J, Kolenda C, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: Cross-sectional findings from the Newcastle 85+ Study. Mech Ageing Dev. 2012;133(6):456-66.

20.Soysal P, Arik F, Smith L, Jackson SE, Isik AT. Inflammation, Frailty and Cardiovascular Disease. Adv Exp Med Biol. 2020;1216:55-64.

21.Streeten EA. Bone as a classic endocrine organ: Interactions with non-bone tissues. Rev Endocr Metab Disord. 2015;16(2):77-8.

22.Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. The cell biology of bone metabolism. J Clin Pathol. 2008;61(5):577-87.

23.Zaidi M, Yuen T, Sun L, Rosen CJ. Regulation of Skeletal Homeostasis. Endocr Rev. 2018;39(5):701-18.

24.Severinsen MCK, Pedersen BK. Muscle-organ crosstalk: the emerging roles of myokines. Endocr Rev. 2020 May 11;41(4):594-609.

25.Colaianni G, Storlino G, Sanesi L, Colucci S, Grano M. Myokines and Osteokines in the Pathogenesis of Muscle and Bone Diseases. Curr Osteoporos Rep. 2020 Jun 8;18:401-7.

26.Li G, Zhang L, Wang D, AIQudsy L, Jiang JX, Xu H, et al. Muscle-bone crosstalk and potential therapies for sarco-osteoporosis. J Cell Biochem. 2019 May 20;120(9):14262-73.

27.Greco EA, Pietschmann P, Migliaccio S. Osteoporosis and Sarcopenia Increase Frailty Syndrome in the Elderly. Front Endocrinol. 2019;10:255.

28.Calvani R, Marini F, Cesari M, Tosato M, Picca A, Anker SD, et al. Biomarkers for physical frailty and sarcopenia. Aging Clin Exp Res. 2017;29(1):29-34.

29.van den Bergh JP, van Geel TA, Geusens PP. Osteoporosis, frailty and fracture: implications for case finding and therapy. Nat Rev Rheumatol. 2012;8(3):163-72.

30.Li G, Thabane L, Papaioannou A, Ioannidis G, Levine MAH, Adachi JD. An overview of osteoporosis and frailty in the elderly. BMC Musculoskelet Disord. 2017;18(1):46.

31.Ecss A, Ecss A. Association of Bone Mineral Density with Frailty, Pre-Frailty, and Osteoporosis in Community-Dwelling Elderly: A Prospective Study. Available from: https://clinmedjournals.org/articles/jgmg/journal-of-geriatric-medicine-and-gerontology-jgmg-3-033.php?jid=jgmg. Accessed 2020 Oct 15.

32.Cook MJ, Oldroyd A, Pye SR, Ward KA, Gielen E, Ravindrarajah R, et al. Frailty and bone health in European men. Age Ageing. 2017;46(4):635-41.

33.Warburton DE, Nicol CW, Gatto SN, Bredin SS. Cardiovascular disease and osteoporosis: Balancing risk management. Vasc Health Risk Manag. 2007;3(5):673-89.

34.McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine. 2004;23(1):1-10.

35.Jackson RD, Mysiw WJ. Insights into the epidemiology of postmenopausal osteoporosis: the Women’s Health Initiative. Semin Reprod Med. 2014;32(6):454-62.

36.Norris CM, Yip CYY, Nerenberg KA, Clavel M‐A, Pacheco C, Foulds HJA, Hardy M, et al. State of the Science in Women’s Cardiovascular Disease: A Canadian Perspective on the Influence of Sex and Gender. J Am Heart Assoc. 2020;9(4):e015634.

37.Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017;5(11):908-23.

38.STROBE Statement: Home. Available from: https://www.strobe-statement.org/index.php?id=strobe-home. Accessed 2020 Oct 15.

39.Boreskie KF, Kehler DS, Costa EC, Cortez PC, Berkowitz I, Hamm NC, et al. Protocol for the HAPPY Hearts study: cardiovascular screening for the early detection of future adverse cardiovascular outcomes in middle-aged and older women: a prospective, observational cohort study. BMJ Open. 2017;7(11):e018249.

40.Boreskie KF, Kehler DS, Costa EC, Hiebert BM, Hamm NC, Moffatt TL, et al. Standardization of the Fried frailty phenotype improves cardiovascular disease risk discrimination. Exp Gerontol. 2019;119:40-4.

41.Duprez DA, Cohn JN. Identifying early cardiovascular disease to target candidates for treatment. J Clin Hypertens Greenwich Conn. 2008;10(3):226-31.

42.D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53.

43.MILLIPLEX MAP Human Bone Magnetic Bead Panel—Bone Metabolism Multiplex Assay. Available from: http://www.emdmillipore.com/CA/en/product/MILLIPLEX-MAP-Human-Bone-Magnetic-Bead-Panel-Bone-Metabolism-Multiplex-Assay,MM_NF-HBNMAG-51K. Accessed 2020 Oct 15.

44.Cornish SM, Chilibeck PD. Alpha-linolenic acid supplementation and resistance training in older adults. Appl Physiol Nutr Metab. 2009;34(1):49-59.

45.Ensrud KE, Ewing SK, Taylor BC, Fink HA, Stone KL, Cauley JA, et al. Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci. 2007;62(7):744-51.

46.Ecss A, Ecss A. Association of Bone Mineral Density with Frailty, Pre-Frailty, and Osteoporosis in Community-Dwelling Elderly: A Prospective Study. Available from: https://clinmedjournals.org/articles/jgmg/journal-of-geriatric-medicine-and-gerontology-jgmg-3-033.php?jid=jgmg. Accessed 2020 Oct 15.

47.Álvarez-Sánchez N, Álvarez-Ríos AI, Guerrero JM, García-García FJ, Rodríguez-Mañas L, Cruz-Chamorro I, et al. Homocysteine levels are associated with bone resorption in pre-frail and frail Spanish women: The Toledo Study for Healthy Aging. Exp Gerontol. 2018 15;108:201-8.

48.Gené Huguet L, Navarro González M, Kostov B, Ortega Carmona M, Colungo Francia C, Carpallo Nieto M, et al. Pre Frail 80: Multifactorial Intervention to Prevent Progression of Pre-Frailty to Frailty in the Elderly. J Nutr Health Aging. 2018;22(10):1266-74.

49.Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016;138(4):984-1010.

50.Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70(1):11-20.

51.Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S. Interleukin-6 Directly Inhibits Osteoclast Differentiation by Suppressing Receptor Activator of NF-κB Signaling Pathways. J Biol Chem. 2008;283(17):11535-40.

52.Lee S-H, Kim T-S, Choi Y, Lorenzo J. Osteoimmunology: cytokines and the skeletal system. BMB Rep. 2008;41(7):495-510.

53.Loi F, Córdova LA, Pajarinen J, Lin T, Yao Z, Goodman SB. Inflammation, Fracture and Bone Repair. Bone. 2016;86:119-30.

54.Fernández-Ruiz I. Immune system and cardiovascular disease. Nat Rev Cardiol. 2016;13(9):503.

55.Wilson D, Jackson T, Sapey E, Lord JM. Frailty and sarcopenia: The potential role of an aged immune system. Ageing Res Rev. 2017;36:1-10.

56.Soysal P, Stubbs B, Lucato P, Luchini C, Solmi M, Peluso R, et al. Inflammation and frailty in the elderly: A systematic review and meta-analysis. Ageing Res Rev. 2016;31:1-8.

57.Nishida H, Horio T, Suzuki Y, Iwashima Y, Tokudome T, Yoshihara F, et al. Interleukin-6 as an independent predictor of future cardiovascular events in high-risk Japanese patients: comparison with C-reactive protein. Cytokine. 2011;53(3):342-6.

58.Zelová H, Hošek J. TNF-α signalling and inflammation: interactions between old acquaintances. Inflamm Res. 2013;62(7):641-51.

59.Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106(12):1481-8.

60.Lu X, Gilbert L, He X, Rubin J, Nanes MS. Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF kappa B pathways. J Biol Chem. 2006;281(10):6297-306.

61.Osta B, Benedetti G, Miossec P. Classical and Paradoxical Effects of TNF-α on Bone Homeostasis. Front Immunol. 2014;5:48.

62.Ferrari R. The role of TNF in cardiovascular disease. Pharmacol Res. 1999;40(2):97-105.

63.Prediction of coronary disease incidence by biomarkers of inflammation, oxidation, and metabolism. Sci Rep. 2018;8:3191.

64.Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun;89(6):2548-56.

65.Rosenbaum M, Leibel RL. Role of leptin in energy homeostasis in humans. J Endocrinol. 2014;223(1):T83-96.

66.Upadhyay J, Farr OM, Mantzoros CS. The role of leptin in regulating bone metabolism. Metabolism. 2015;64(1):105-13.

67.Cirmanová V, Bayer M, Stárka L, Zajícková K. The effect of leptin on bone: an evolving concept of action. Physiol Res. 2008;57(Suppl 1):S143-51.

68.Isaia GC, D’Amelio P, Di Bella S, Tamone C. Is leptin the link between fat and bone mass? J Endocrinol Invest. 2005;28(10 Suppl):61-5.

69.Turner RT, Kalra SP, Wong CP, Philbrick KA, Lindenmaier LB, Boghossian S, et al. Peripheral Leptin Regulates Bone Formation. J Bone Miner Res. 2013;28(1):22-34.

70.Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100(2):197-207.

71.Koh KK, Park SM, Quon MJ. Leptin and Cardiovascular Disease. Circulation. 2008;117(25):3238-49.

72.Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001;104(25):3052-6.

73.Andrade-Oliveira V, Câmara NOS, Moraes-Vieira PM. Adipokines as Drug Targets in Diabetes and Underlying Disturbances. J Diabetes Res. 2015;2015:681612.

74.Shetty S, Kapoor N, Bondu JD, Thomas N, Paul TV. Bone turnover markers: Emerging tool in the management of osteoporosis. Indian J Endocrinol Metab. 2016;20(6):846-52.

75.Saedi AA, Feehan J, Phu S, Duque G. Current and emerging biomarkers of frailty in the elderly. Clin Interv Aging. 2019;14:389-98.

76.Greenblatt MB, Tsai JN, Wein MN. Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. Clin Chem. 2017;63(2):464-74.

77.Coelho-Junior HJ, Picca A, Calvani R, Uchida MC, Marzetti E. If my muscle could talk: Myokines as a biomarker of frailty. Exp Gerontol. 2019;127:110715.

引用本文

Kevin F. Boreskie,Christopher J. Oldfield,Liam A.Thompson,Teri L. Moffatt,Brett M. Hiebert,Rakesh C. Arora,Todd A. Duhamel*. Bone Metabolism Analytes as Biomarkers of Pre-Frailty and Cardiovascular Disease Risk in Females, Advances in Geriatric Medicine and Research. 2020; 2; (4). https://doi.org/10.20900/agmr20200025.

文献评论

相关学者

相关机构